替尔泊肽与GLP-1受体激动剂在2型糖尿病患者中的临床结局
该回顾性队列研究利用美国TriNetX协作网络数据,纳入2022年6月1日至2023年6月30日启动替尔泊肽或GLP-1受体激动剂治疗的18岁及以上2型糖尿病患者,排除基线5期慢性肾脏病或肾衰竭者及用药前60天内发生心肌梗死或缺血性/出血性卒中者。替尔泊肽组14 834例,GLP-1受体激动剂组125 474例,中位随访10.5个月。替尔泊肽组全因死亡0.6%(95例),GLP-1受体激动剂组1.1%(166例);替尔泊肽与更低的全因死亡风险(AHR 0.58;95%CI 0.45-0.75)、主要不良心血管事件(AHR 0.80;95%CI 0.71-0.91)、主要不良心血管事件与全因死亡复合终点(AHR 0.76;95%CI 0.68-0.84)、肾脏事件(AHR 0.52;95%CI 0.37-0.73)、急性肾损伤(AHR 0.78;95%CI 0.70-0.88)及主要不良肾脏事件(AHR 0.54;95%CI 0.44-0.67)相关。替尔泊肽组糖化血红蛋白降幅更大(治疗差异-0.34个百分点;95%CI -0.44至-0.24个百分点),体重降幅更大(治疗差异-2.9 kg;95%CI -4.8至-1.1 kg)。亚组交互检验显示按估算肾小球滤过率、糖化血红蛋白水平、体重指数、合并用药和合并症分层结果一致。作者认为这些发现支持将替尔泊肽纳入该人群的治疗策略。
要点
- 替尔泊肽组全因死亡0.6%(95例)vs GLP-1受体激动剂组1.1%(166例),AHR 0.58(95%CI 0.45-0.75)。
- 替尔泊肽与更低的主要不良心血管事件风险相关(AHR 0.80;95%CI 0.71-0.91)。
- 替尔泊肽与更低的急性肾损伤(AHR 0.78;95%CI 0.70-0.88)和主要不良肾脏事件(AHR 0.54;95%CI 0.44-0.67)风险相关。
- 替尔泊肽组糖化血红蛋白降幅多降低0.34个百分点(95%CI -0.44至-0.24个百分点),体重多降低2.9 kg(95%CI -4.8至-1.1 kg)。
- 亚组交互检验显示按估算肾小球滤过率、糖化血红蛋白、体重指数、合并用药和合并症分层结果一致。
适用人群与场景
- 美国TriNetX协作网络中18岁及以上2型糖尿病患者,于2022年6月1日至2023年6月30日启动替尔泊肽或GLP-1受体激动剂治疗。
- 排除基线5期慢性肾脏病或肾衰竭者,以及用药前60天内发生心肌梗死或缺血性/出血性卒中者。
研究设计与关键结果
- 回顾性队列研究,替尔泊肽组14 834例(平均[SD]年龄55.4[11.8]岁;女性8444例[56.9%]),GLP-1受体激动剂组125 474例(平均[SD]年龄58.1[13.3]岁;女性67 474例[53.8%])。
- 中位随访10.5个月(IQR 5.2-15.7个月),替尔泊肽组死亡95例(0.6%),GLP-1受体激动剂组死亡166例(1.1%)。
- 替尔泊肽与更低的全因死亡风险相关(AHR 0.58;95%CI 0.45-0.75)。
- 替尔泊肽与更低的主要不良心血管事件风险相关(AHR 0.80;95%CI 0.71-0.91)。
- 替尔泊肽与更低的主要不良心血管事件与全因死亡复合终点风险相关(AHR 0.76;95%CI 0.68-0.84)。
- 替尔泊肽与更低的肾脏事件(AHR 0.52;95%CI 0.37-0.73)、急性肾损伤(AHR 0.78;95%CI 0.70-0.88)和主要不良肾脏事件(AHR 0.54;95%CI 0.44-0.67)风险相关。
- 与GLP-1受体激动剂相比,替尔泊肽组糖化血红蛋白降低更多(治疗差异-0.34个百分点;95%CI -0.44至-0.24个百分点),体重降低更多(治疗差异-2.9 kg;95%CI -4.8至-1.1 kg)。
- 亚组分析交互检验显示按估算肾小球滤过率、糖化血红蛋白水平、体重指数、合并用药和合并症分层结果一致。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现支持将替尔泊肽纳入2型糖尿病患者的治疗策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Despite its demonstrated benefits in improving cardiovascular risk profiles, the association of tirzepatide with mortality and cardiovascular and kidney outcomes compared with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) remains unknown.
OBJECTIVE: To investigate the association of tirzepatide with mortality and adverse cardiovascular and kidney outcomes compared with GLP-1 RAs in patients with type 2 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used US Collaborative Network of TriNetX data collected on individuals with type 2 diabetes aged 18 years or older initiating tirzepatide or GLP-1 RA between June 1, 2022, and June 30, 2023; without stage 5 chronic kidney disease or kidney failure at baseline; and without myocardial infarction or ischemic or hemorrhagic stroke within 60 days of drug initiation.
EXPOSURES: Treatment with tirzepatide compared with GLP-1 RA.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, and secondary outcomes included major adverse cardiovascular events (MACEs), the composite of MACEs and all-cause mortality, kidney events, acute kidney injury, and major adverse kidney events. All outcomes were analyzed using Cox proportional hazards regression models.
RESULTS: There were 14 834 patients treated with tirzepatide (mean [SD] age, 55.4 [11.8] years; 8444 [56.9%] female) and 125 474 treated with GLP-1 RA (mean [SD] age, 58.1 [13.3] years; 67 474 [53.8%] female). After a median (IQR) follow-up of 10.5 (5.2-15.7) months, 95 patients (0.6%) in the tirzepatide group and 166 (1.1%) in the GLP-1 RA group died. Tirzepatide treatment was associated with lower hazards of all-cause mortality (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75), MACEs (AHR, 0.80; 95% CI, 0.71-0.91), the composite of MACEs and all-cause mortality (AHR, 0.76; 95% CI, 0.68-0.84), kidney events (AHR, 0.52; 95% CI, 0.37-0.73), acute kidney injury (AHR, 0.78; 95% CI, 0.70-0.88), and major adverse kidney events (AHR, 0.54; 95% CI, 0.44-0.67). Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, -0.34 percentage points; 95% CI, -0.44 to -0.24 percentage points) and body weight (treatment difference, -2.9 kg, 95% CI, -4.8 to -1.1 kg) compared with GLP-1 RA. An interaction test for subgroup analysis revealed consistent results stratified by estimated glomerular filtration rate, glycated hemoglobin level, body mass index, comedications, and comorbidities.
CONCLUSIONS AND RELEVANCE: In this study, treatment with tirzepatide was associated with lower hazards of all-cause mortality, adverse cardiovascular events, acute kidney injury, and adverse kidney events compared with GLP-1 RA in patients with type 2 diabetes. These findings support the integration of tirzepatide into therapeutic strategies for this population.
参考来源
- Chuang MH, Chen JY, Wang HY, et al. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw Open. 2024. PMID: 39133485. doi:10.1001/jamanetworkopen.2024.27258
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。